Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Non-Myeloablative HSCT with Alemtuzumab, Fludarabine, and Melphalan
NCT00027560Phase 2Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Jul 2001
- Primary completion
- Apr 2009
- Modality
- Monoclonal Antibodies, Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of alemtuzumab, fludarabine and melphalan in non-Hodgkin lymphoma (NHL), chronic lymphocytic leukemia (CLL), Hodgkin lymphoma (HL) and 5 more, sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoints: Overall Survival at 24 months and Acute Graft-versus-Host Disease at 4 months. Started Jul 2001; status: completed.
02
Drugs
alemtuzumabfludarabinemelphalan
03
Conditions
non-Hodgkin lymphoma (NHL)chronic lymphocytic leukemia (CLL)Hodgkin lymphoma (HL)multiple myeloma (MM)Waldenstrom macroglobulinemia (WM)
Beyond the preview
Go deeper on NCT00027560.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00027560.